CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.

T cells’ abilities to recognize molecular targets and orchestrate cytotoxic and immunomodulatory functions has made them attractive therapeutic tools, especially for cancer treatment. From CAR-T to ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

As people age, their immune system function declines. T cell populations become smaller and can’t react to pathogens as quickly, making individuals more susceptible to a variety of infections. To try ...